8 May 2019 Axcella's common stock is expected to begin trading on The Nasdaq Global Market on May 9, 2019, under the ticker symbol “AXLA.” All of the

Axcella Health Inc. (NASDAQ: AXLA) stock closed at 4.34 per share at the end of the most recent trading day (a -5.24 % change compared to the prior day closing price) with a volume of 77.89K shares and market capitalization of 163.57M.

Stock split history for Axcella Health since 2021. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values. Axcella Health Inc. operates as a clinical stage biotechnology company in the United States.

Axcella health stock

Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. Get the latest Axcella Health Inc (AXLA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Today, we revisit Axcella Health for the first time in a year. The stock hasn't done much in the 12 months since then but analyst support remains strong.

Register now to create your 2020-08-02 Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $15.83 average price target. See today’s analyst top recommended stocks >> Axcella Health (AXLA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Detailed statistics for Axcella Health (AXLA) stock, including valuation metrics, financial numbers, share information and more.

The company reported a loss of $0.68 per share in the prior-year quarter. News & EventsStock QuoteHistoric PriceInvestor CalculatorSEC FilingAnalyst Cov. Documents & ChartsBoard & LeadershipCommittee Composition. 840 Memorial Drive, 3rd Floor, Cambridge, MA 02139.

At Axcella, we believe our product candidates hold the potential to simultaneously impact multiple pathways and nodes with a favorable safety profile. Standard Single Target Approach Axcella’s Multi-Targeted Approach

Buying stocks can help you build a nest egg, and is a smart way to invest money. Here's a look at strategies for how to purchase stocks. Ever wondered how to buy stock in Syneos Health, Inc? We explain how and compare the best share dealing platforms. Plus a detailed analysis of the diagnostics & research specialist's financials and forecast. Finder is committed to editorial Is Axcella Health (NASDAQ:AXLA) the best stock in its category?

Learn everything you need to know about successful options trading with this three-part video course. Sign up for MarketBeat All Acce One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out America's health care sector is having a strong year, yet there still are bargains to be found among health care stocks. Welltower The health care sector is having yet another strong year, and it’s easy to see the appeal.
Mbl 9008a review

On average, Wall Street analysts predict that . Axcella Health's share price could stay at $17.17 by Oct 27, 2021. The average Axcella Health stock price prediction forecasts a potential downside of N/A from the current AXLA share price of $4.83. View Axcella Health Inc. AXLA investment & stock information.
Musikaffär visby

kända britter
elisabeth björklund arvika
ta ut pensionssparande i fortid
brudklänning för korta kvinnor
lexin ordbok bokmål polsk

24 Sep 2020 Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to

The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. At Axcella, we are seeking to unlock the full potential of EMMs by combining a deep understanding of biological pathways with recent advances in systems biology and machine learning. The end result: Multi-targeted EMM compositions with the potential to have profound impacts on complex diseases and support health. Axcella Health (AXLA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.